{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Childhood+Glioblastoma", "query": { "condition": "Childhood Glioblastoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1365, "total_pages": 137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Childhood+Glioblastoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T02:04:42.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00301418", "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301418" }, { "nct_id": "NCT02078648", "title": "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Brain Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "SL-701 + GM-CSF", "type": "DRUG" }, { "name": "Imiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemline Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2014-05", "completion_date": "2018-01-22", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02078648" }, { "nct_id": "NCT01480050", "title": "Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "3'-deoxy-3'-[18F]fluorothymidine", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "Mibefradil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 28, "start_date": "2012-05-31", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2019-05-22", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01480050" }, { "nct_id": "NCT00110032", "title": "Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Central Nervous System Germ Cell Tumor", "Adult Choroid Plexus Tumor", "Adult Craniopharyngioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade I Meningioma", "Adult Grade II Meningioma", "Adult Grade III Meningioma", "Adult Medulloblastoma", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Pineoblastoma", "Adult Pineocytoma", "Adult Subependymoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", "Meningeal Melanocytoma" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fluorine F 18 EF5", "type": "RADIATION" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110032" }, { "nct_id": "NCT03551249", "title": "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioma", "Glioblastoma" ], "interventions": [ { "name": "Focused ultrasound (FUS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "InSightec", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2019-03-26", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551249" }, { "nct_id": "NCT00619112", "title": "Temozolomide in Treating Patients With Recurrent High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Central Nervous System Neoplasm" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-10", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619112" }, { "nct_id": "NCT03194971", "title": "NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Tumor samples from patients treated with TTFields at initial diagnosis.", "type": "OTHER" }, { "name": "Tumor samples from patients treated with TTFields at tumor recurrence.", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-06-01", "completion_date": "2023-06-04", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194971" }, { "nct_id": "NCT06333899", "title": "Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "High Grade Glioma", "Diffuse Intrinsic Pontine Glioma", "Anaplastic Astrocytoma", "Infant Type Hemispheric Glioma", "Glioblastoma", "Glioblastoma Multiforme", "WHO Grade III Glioma", "WHO Grade IV Glioma", "Diffuse Midline Glioma, H3K27-altered" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Lorlatinib with chemotherapy1", "type": "DRUG" }, { "name": "Lorlatinib with chemotherapy 2", "type": "DRUG" }, { "name": "Lorlatinib post Radiation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "2025-08-03", "completion_date": "2035-06-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 10, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06333899" }, { "nct_id": "NCT00004004", "title": "Procarbazine in Treating Patients With Recurrent Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "procarbazine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Approaches to Brain Tumor Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004004" }, { "nct_id": "NCT00687765", "title": "Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "bsi-201 plus temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2008-07", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2022-09-14", "last_synced_at": "2026-06-27T02:04:42.451Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00687765" } ] }